Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1948-1955

  Kerdpin, Oranun ^a,b   Mackenzie, Peter I ^a   Bowalgaha, Kushari ^a   Finel, Moshe ^c   Miners, John O ^a,d  

^a FLINDERS UNIVERSITY   (Australia)

^b NARESUAN UNIVERSITY   (Thailand)

^c UNIVERSITY OF HELSINKI   (Finland)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 NITROPYRENE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B7; HISTIDINE; HYMECROMONE; LAMOTRIGINE; MUTANT PROTEIN; NAPROXEN; PROLINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; EMBRYO; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CELL LINE; COTININE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HISTIDINE; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; NAPROXEN; PROLINE; SUBSTRATE SPECIFICITY;

EID: 70349089346     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028225     Document Type: Article

References (36)

1. Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, and Ouzzine M (2007) Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7: identification of critical aromatic amino acid residue at position 33. FEBS J 274:1256-1264. (Pubitemid 46246600)
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433. (Pubitemid 41428474)
3. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, and Lazarus P (2007) Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 codon 67 (Asp>Tyr) polymorphism. Cancer Res 67:9024-9029. (Pubitemid 47535885)
4. Chen G, Dellinger RW, Sun D, Spratt TE, and Lazarus P (2008) Glucuronidation of tobaccospecific nitrosamines by UGT2B10. Drug Metab Dispos 36:824-830.
5. Dubois SG, Beaulieu M, Levesque E, Hum DW, and Belanger A (1999) Alteration of human UDP-glucuronosyltransferase UGT2B17 regio-selectivity by a single amino acid substitution. J Mol Biol 289:29-39. (Pubitemid 29278361)
6. Jin CJ, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 194:496-503. (Pubitemid 23237963)
7. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, and Finel M (2007) Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol 72:761-768. (Pubitemid 47347311)
8. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
9. Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, and Miners JO (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72:1054-1062. (Pubitemid 47481428)
10. Lewis BC, Mackenzie PI, Elliot DJ, Burchell B, Bhasker CR, and Miners JO (2007) Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol 73:1463-1473. (Pubitemid 46452582)
11. Li C and Wu Q (2007) Adaptive evolution of multiple variable exons and structural diversity of drug-metabolizing enzymes. BMC Evol Biol 7:69. (Pubitemid 46876381)
12. Li D, Fournel-Gigleux S, Barré L, Mulliert G, Netter P, Magdalou J, and Ouzzine M (2007) Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferase 1A. J Biol Chem 282:36514-36524.
13. Li Q, Lou X, Peyronneau MA, Straub PO, and Tukey RH (1997) Expression and functional domains of rabbit liver UDP-glucuronosyltransferase 2B16 and 2B13. J Biol Chem 272:3272-3279. (Pubitemid 27066819)
14. Locuson CW and Tracy TS (2007) Comparative modeling of the human UDP-glucuronosyltransferases: insights into structure and mechanism. Xenobiotica 37:155-168. (Pubitemid 46269618)
15. Mackenzie PI (1990) Expression of chimeric cDNAs in cell culture defines a region of UDP-glucuronosyltransferase involved in substrate selection. J Biol Chem 265:3232-3235.
16. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene family. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
17. Martineau I, Tchernof A, and Bélanger A (2004) Amino acid residue Ile211 is essential for the enzymatic activity of human UDP- glucuronosyltransferase 1A10 (UGT1A10). Drug Metab Dispos 32:455-459. (Pubitemid 38420281)
18. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, and Redinbo MR (2007) Crystal structure of the cofactor binding domain of the human phase II drug metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369:498-511. (Pubitemid 46678060)
19. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
20. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
21. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
22. Patana AS, Kurkela M, Finel M, and Goldman A (2008) Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases. Protein Eng Des Sel 21:537-543.
23. Patana AS, Kurkela M, Goldman A, and Finel M (2007) The human UDP-glucuronosyltransferase: identification of key residues within the nucleotide sugar binding site. Mol Pharmacol 72:604-611. (Pubitemid 47347295)
24. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferase. Drug Metab Rev 31:817-899.
25. Ritter JK, Chen F, Sheen YY, Lubet RA, and Owens IS (1993) Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochemistry 31:3409-3414.
26. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, and Owens IS (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257-3261.
27. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062. (Pubitemid 43763765)
28. Senay C, Jedlitschky G, Terrier N, Burchell B, Magdalou J, and Fournel-Gigleux S (2002) The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. Biochim Biophys Acta 1597:90-96.
29. Sorich MJ, McKinnon RA, Miners JO, and Smith PA (2006) The importance of local chemical structure for chemical metabolism by uridine 5′-diphosphate glucuronosyltransferase. J Chem Inf Model 46:2692-2697.
30. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases; evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089. (Pubitemid 37048278)
31. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)
32. Turgeon D, Chouinard S, Belanger P, Picard S, Labbe JF, Borgeat P, and Belanger A (2003) Glucuronidation of arachidonic acid and linoleic acid metabolites by human UDP-glucuronosyltransferases. J Lipid Res 44:1182-1191. (Pubitemid 37279636)
33. Uchaipichat V, Mackenzie PI, Elliot DJ, and Miners JO (2006) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine and sulfinpyrazone) 'probes' for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
34. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423. (Pubitemid 38420275)
35. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, and Miners JO (2007) Influence of mutations associated with Gilbert and Crigler Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A (UGT1A) substrates. Pharmacogenet Genomics 17:1017-1029. (Pubitemid 351339486)
36. Xiong Y, Bernardi D, Bratton S, Ward MD, Battaglia E, Finel M, Drake RR, and Radominska- Pandya A (2006) Phenylalanine 90 and 93 are localized within the phenol binding site of human UDP-glucuronosyltransferase 1A10 as determined by photoaffinity labeling, mass spectrometry, and site-directed mutagenesis. Biochemistry 45:2322-2332. (Pubitemid 43271332)